These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 32548831)

  • 1. Immunofluorescence-Based Analysis of Caveolin-3 in the Diagnostic Management of Neuromuscular Diseases.
    Roos A; Hathazi D; Schara U
    Methods Mol Biol; 2020; 2169():197-216. PubMed ID: 32548831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Role for Caveolin-3 in the Pathogenesis of Muscular Dystrophies.
    Pradhan BS; Prószyński TJ
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33228026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caveolinopathies: translational implications of caveolin-3 in skeletal and cardiac muscle disorders.
    Gazzerro E; Bonetto A; Minetti C
    Handb Clin Neurol; 2011; 101():135-42. PubMed ID: 21496630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAV3 mutations causing exercise intolerance, myalgia and rhabdomyolysis: Expanding the phenotypic spectrum of caveolinopathies.
    Scalco RS; Gardiner AR; Pitceathly RD; Hilton-Jones D; Schapira AH; Turner C; Parton M; Desikan M; Barresi R; Marsh J; Manzur AY; Childs AM; Feng L; Murphy E; Lamont PJ; Ravenscroft G; Wallefeld W; Davis MR; Laing NG; Holton JL; Fialho D; Bushby K; Hanna MG; Phadke R; Jungbluth H; Houlden H; Quinlivan R
    Neuromuscul Disord; 2016 Aug; 26(8):504-10. PubMed ID: 27312022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and muscle pathology in a series of caveolinopathy patients.
    Fulizio L; Nascimbeni AC; Fanin M; Piluso G; Politano L; Nigro V; Angelini C
    Hum Mutat; 2005 Jan; 25(1):82-9. PubMed ID: 15580566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical and pathological changes result from mutated Caveolin-3 in muscle.
    González Coraspe JA; Weis J; Anderson ME; Münchberg U; Lorenz K; Buchkremer S; Carr S; Zahedi RP; Brauers E; Michels H; Sunada Y; Lochmüller H; Campbell KP; Freier E; Hathazi D; Roos A
    Skelet Muscle; 2018 Aug; 8(1):28. PubMed ID: 30153853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caveolinopathies: from the biology of caveolin-3 to human diseases.
    Gazzerro E; Sotgia F; Bruno C; Lisanti MP; Minetti C
    Eur J Hum Genet; 2010 Feb; 18(2):137-45. PubMed ID: 19584897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caveolin-3 T78M and T78K missense mutations lead to different phenotypes in vivo and in vitro.
    Traverso M; Gazzerro E; Assereto S; Sotgia F; Biancheri R; Stringara S; Giberti L; Pedemonte M; Wang X; Scapolan S; Pasquini E; Donati MA; Zara F; Lisanti MP; Bruno C; Minetti C
    Lab Invest; 2008 Mar; 88(3):275-83. PubMed ID: 18253147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A CAV3 microdeletion differentially affects skeletal muscle and myocardium.
    Cagliani R; Bresolin N; Prelle A; Gallanti A; Fortunato F; Sironi M; Ciscato P; Fagiolari G; Bonato S; Galbiati S; Corti S; Lamperti C; Moggio M; Comi GP
    Neurology; 2003 Dec; 61(11):1513-9. PubMed ID: 14663034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myotonia associated with caveolin-3 mutation.
    Milone M; McEvoy KM; Sorenson EJ; Daube JR
    Muscle Nerve; 2012 Jun; 45(6):897-900. PubMed ID: 22581547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel missense mutation in CAV3 gene in an Italian family with persistent hyperCKemia, myalgia and hypercholesterolemia: Double-trouble.
    Bruno G; Puoti G; Oliva M; Colavito D; Allegorico L; Napolitano F; Sampaolo S
    Clin Neurol Neurosurg; 2020 Apr; 191():105687. PubMed ID: 32004987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dystrophy-associated caveolin-3 mutations reveal that caveolae couple IL6/STAT3 signaling with mechanosensing in human muscle cells.
    Dewulf M; Köster DV; Sinha B; Viaris de Lesegno C; Chambon V; Bigot A; Bensalah M; Negroni E; Tardif N; Podkalicka J; Johannes L; Nassoy P; Butler-Browne G; Lamaze C; Blouin CM
    Nat Commun; 2019 Apr; 10(1):1974. PubMed ID: 31036801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caveolin and NOS in the Development of Muscular Dystrophy.
    Nakashima M; Suga N; Yoshikawa S; Matsuda S
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accumulation of caveolin-3 protein is limited in damaged muscle in chicken muscular dystrophy.
    Matsumoto H; Sasazaki S; Fujiwara A; Ichihara N; Kikuchi T; Mannen H
    Comp Biochem Physiol A Mol Integr Physiol; 2010 Sep; 157(1):68-72. PubMed ID: 20451648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caveolae and caveolin-3 in muscular dystrophy.
    Galbiati F; Razani B; Lisanti MP
    Trends Mol Med; 2001 Oct; 7(10):435-41. PubMed ID: 11597517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caveolinopathies: mutations in caveolin-3 cause four distinct autosomal dominant muscle diseases.
    Woodman SE; Sotgia F; Galbiati F; Minetti C; Lisanti MP
    Neurology; 2004 Feb; 62(4):538-43. PubMed ID: 14981167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caveolin-3 is a direct molecular partner of the Cav1.1 subunit of the skeletal muscle L-type calcium channel.
    Couchoux H; Bichraoui H; Chouabe C; Altafaj X; Bonvallet R; Allard B; Ronjat M; Berthier C
    Int J Biochem Cell Biol; 2011 May; 43(5):713-20. PubMed ID: 21262376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caveolin-3 regulates the activity of Ca
    Matsunobe M; Motohashi N; Aoki E; Tominari T; Inada M; Aoki Y
    Am J Physiol Cell Physiol; 2022 Oct; 323(4):C1137-C1148. PubMed ID: 35993515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A caveolin-3 mutant that causes limb girdle muscular dystrophy type 1C disrupts Src localization and activity and induces apoptosis in skeletal myotubes.
    Smythe GM; Eby JC; Disatnik MH; Rando TA
    J Cell Sci; 2003 Dec; 116(Pt 23):4739-49. PubMed ID: 14600260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysferlin in a hyperCKaemic patient with caveolin 3 mutation and in C2C12 cells after p38 MAP kinase inhibition.
    Capanni C; Sabatelli P; Mattioli E; Ognibene A; Columbaro M; Lattanzi G; Merlini L; Minetti C; Maraldi NM; Squarzoni S
    Exp Mol Med; 2003 Dec; 35(6):538-44. PubMed ID: 14749532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.